NASA Awards Redwire $4 Million In Additional Funding to Support Trailblazing Drug Development in Microgravity

Key Terms

microgravity medical

Microgravity is a condition where objects experience almost no net weight because they are in continuous free-fall, such as aboard orbiting spacecraft; think of passengers feeling weightless in a smoothly falling elevator. For investors, microgravity matters because it enables scientific experiments and manufacturing processes that behave very differently than on Earth, potentially creating novel drugs, materials, or technologies, changing development timelines, costs, market opportunities and regulatory considerations.

indefinite-delivery/indefinite-quantity regulatory

An indefinite-delivery/indefinite-quantity (IDIQ) contract is a purchasing agreement used mainly by governments where the buyer commits to buy goods or services over a set time but does not specify exact quantities or delivery dates up front. For investors this matters because an IDIQ can create a steady pipeline of potential orders and recurring revenue like a standing grocery list a store can draw from, while leaving total future sales and timing uncertain.

adar1 inhibitor medical

An ADAR1 inhibitor is a drug that blocks the enzyme ADAR1, which normally edits RNA inside cells and can mask abnormal RNA signals. Preventing that editing can make tumor or infected cells more visible to the immune system, creating a new way to treat disease; for investors this means potential high reward if effective but also notable safety and development risk, like turning off a spell‑checker so mistakes become obvious but may cause collateral problems.

JACKSONVILLE, Fla.--(BUSINESS WIRE)-- Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, today announced that NASA has awarded the company an additional $4 million to support new drug development investigations on the International Space Station (ISS) using Redwire’s Pharmaceutical In-space Laboratory (PIL-BOX) technology. This additional funding expands an existing task order under a $25 million, five-year indefinite-delivery/indefinite-quantity contract through NASA’s In Space Production Applications (InSPA) program.

“The space and pharmaceutical industries are coming together in a way that will transform both fields,” said Mike Gold, President of Redwire’s Space business segment. “NASA and the InSPA program are playing a critical role by acting as a catalyst for revolutionary new public and private sector capabilities, and we’re proud and grateful that they have selected Redwire to implement this work tackling diseases ranging from cancer to osteoporosis and obesity. By going to space, together with our NASA partners, we can improve life on Earth.”

With 43 units flown, PIL-BOX has contributed to the growth of high‑quality crystals that could transform how lifesaving medicines are developed. Redwire recently supported a cancer therapy investigation led by Aspera Biomedicines (Aspera) that launched aboard the SpaceX Crew-12 mission to the ISS. Aspera and Redwire are using PIL‑BOX to advance development of Rebecsinib, an ADAR1 inhibitor. Results from the investigation have the potential to enable new drug formulations that will provide broader cancer treatment options.

By supporting partners such as Aspera, Bristol Myers Squibb, Eli Lilly and Company, ExesaLibero Pharma, Purdue University, and Butler University, Redwire is helping drive a new era of biotechnology where microgravity unlocks insights that can improve treatments for some of the world’s most challenging diseases.

About Redwire

Redwire Corporation (NYSE:RDW) is an integrated space and defense tech company focused on advanced technologies. We are building the future of aerospace infrastructure, autonomous systems, and multi-domain operations leveraging digital engineering and AI automation. Redwire’s approximately 1,400 employees located throughout North America and Europe are committed to delivering innovative space and airborne platforms transforming the future of multi-domain operations. For more information, please visit RDW.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260311373158/en/

Media Contact:

Tere Riley

Tere.Riley@rdw.com

OR

Investors:

Investorrelations@rdw.com

Source: Redwire Corporation